Clarity Pharmaceuticals (ASX:CU6) has taken another step toward the commercialisation of its prostate cancer imaging agent, signing a manufacturing agreement that significantly broadens its production capacity and geographic reach.
The deal with Nucleus RadioPharma marks the continuation of an existing partnership and reflects growing confidence in the potential of 64Cu-SAR bisPSMA as it advances toward regulatory approval.
The agreement centres on Nucleus RadioPharma’s facility in Rochester, Minnesota, which is already capable of producing tens of thousands of patient doses annually, alongside a planned expansion in Spring House, Pennsylvania.
Once operational, the Pennsylvania site is expected to dramatically scale output and extend distribution across the northeastern United States. Together, the facilities are designed to support nationwide supply and international distribution, positioning the product for broad commercial access.
This latest arrangement builds on earlier agreements between the two companies, including a master services agreement and a clinical supply deal signed in late 2024. The evolving partnership underscores a shared strategy to establish a robust manufacturing network ahead of anticipated market demand, particularly as the product progresses through late-stage clinical trials and approaches a potential regulatory submission.
For Nucleus RadioPharma, the collaboration represents an opportunity to bring a next-generation diagnostic tool into wider clinical use.
Geoffrey Johnson, Chief Scientific Officer, said, “Nucleus RadioPharma is excited to produce a next-generation diagnostic imaging agent, 64Cu-SAR-bisPSMA, that data shows is capable of visualising tiny prostate cancer lesions that the current standard of care prostate specific membrane antigen (PSMA) positron emission tomography (PET) fails to detect. Earlier cancer detection and better cancer staging directly affects patient management and treatment outcomes and I firmly believe that seeing is saving. At Nucleus RadioPharma, we are proud to be driving demonstrable advances at the cutting edge of theranostics.”
Stephen Hahn, Chief Executive Officer of Nucleus RadioPharma, highlighted the product's momentum and its potential to reshape diagnostic pathways. “We are pleased to continue growing our partnership with Clarity through this new Commercial Manufacturing Agreement. At Nucleus RadioPharma, we share Clarity’s goal of improving treatment outcomes for patients with cancer and look forward to delivering novel products to people in need of better diagnostic and therapeutic options. 64Cu-SAR-bisPSMA is now quickly approaching its market launch, and with recently released data highlighting its detection benefits in comparison to standard of care PSMA PET, we could not be more excited about being part of the change in shaping the future of prostate cancer diagnostics.”
Clarity’s leadership views the agreement as a cornerstone of its broader supply strategy. Executive Chairperson Dr Alan Taylor emphasised the importance of scaling production capacity ahead of launch, noting that the company is preparing to meet not only existing demand but also a larger patient population enabled by improved diagnostic performance. He pointed to the advantages of copper-64, including its half-life, which enables flexible manufacturing and distribution models that better match clinical needs across regions.
The company has been steadily assembling a network of manufacturing and supply partners across the United States, including agreements for copper 64 production and additional commercial manufacturing arrangements. The goal is to create a tiered, regionally distributed system that delivers reliable, timely access to radiopharmaceuticals at scale.
Taylor also underscored the strategic value of the partnership itself. “Nucleus RadioPharma is a trusted partner with extensive expertise in radiopharmaceuticals across not only the supply and manufacturing side, but also with a unique insight into the impact that radiopharmaceuticals can have on the healthcare system, treating clinicians and their patients. We look forward to continuing to work with their team as we continue to deliver on our promise of improving treatment outcomes for patients with cancer.”